Sign Up
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Moderna receives U.S. FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2

Written by | 19 Sep 2025 | COVID-19

Moderna Inc. announced that the FDA has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.

The updated formula for Spikevax is now approved for individuals 6 months – 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. mNEXSPIKE, Moderna’s new COVID-19 vaccine, is approved for individuals 12 -64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. With the U.S. FDA’s decision, Moderna’s updated vaccines are expected to be available in the coming days.

“Protecting people at increased risk of severe outcomes from COVID-19 is imperative to public health as COVID-19 was responsible for up to 4 million outpatient visits and nearly half of a million hospitalizations last year,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are proud to help ensure Americans will have the latest protection against currently circulating strains this respiratory virus season.”

The updated vaccine composition is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be developed with a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.

Moderna’s updated COVID-19 vaccines targeting LP.8.1 have already been granted approval by regulators in Canada, Europe, Japan, Switzerland and other countries. Additional regulatory applications are under review around the world in preparation for the coming season.

Newsletter Icon

Register for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.